Template:Emtricitabine rilpivirine tenofovir: Difference between revisions
Jump to navigation
Jump to search
Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8..." |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 17: | Line 17: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Emtricitabine rilpivirine tenofovir adverse reactions|Adverse Reactions]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Emtricitabine rilpivirine tenofovir adverse reactions|Adverse Reactions]] | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Emtricitabine rilpivirine tenofovir drug interactions|Drug Interactions]] | |||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Emtricitabine rilpivirine tenofovir overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Emtricitabine rilpivirine tenofovir overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Emtricitabine rilpivirine tenofovir dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Emtricitabine rilpivirine tenofovir dosage and administration|Dosage and Administration]] | ||